Which Billionaire Fund Manager Likes Horizon Pharma?

FARALLON CAPITALIn a 13G filing last week, billionaire fund manager Thomas Steyer of Farallon Capital Management announced that his firm now had a 5.4% ownership stake in Horizon Pharma Inc. (NASDAQ:HZNP)—buying almost 1.9 million shares. Steyer founded Farallon in 1986 and previously worked for Goldman Sachs and Morgan Stanley.

The Farallon news come in conjunction with other recent reports that notable pharmaceutical investors Tang Capital and Sutter Hill Ventures took a 9.9% and 6.1% stake, respectively, in Horizon Pharma. Tang Capital is also a large shareholder in Penwest Pharmaceuticals and A.P. Pharma, and Sutter Hill is a notable investor in Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), which is up almost 500% year to date.

The company announced an agreement with Merck earlier this year to co-develop and commercialize TH-302—a hypoxia-targeted drug. Threshold is set to receive an upfront payment of $25 million and could receive up to $35 million in additional development milestones during 2012. Next year EPS for the company is still in the red, with estimated 2013 EPS of negative $0.21, but this would still mean a 87% gain from the previous year.

The Horizon stake represents a new position for Farallon, which took positions in other biopharmaceutical companies during 2Q, Amylin Pharmaceuticals and Merrimack Pharmaceuticals Inc (NASDAQ:MACK) among them. Merrimack has a focus on developing medicines to treat serious diseases, with a particular focus on cancer. Up 50% year to date, the company is also like the other pharma companies mentioned, operating at a negative EPS. Next year EPS is expected to be negative $0.91, but up 50% year over year.

Horizon is a biopharmaceutical company, developing medicines targeting arthritis, but is flat year to date. Horizon’s 2Q results put the company’s revenues up to $3.8 million, compared to the same quarter in 2011 at $1.3 million. As well, the company continued its string of net losses, posting a net loss of $22.8 million, or negative EPS of $0.68.

In July, Horizon announced FDA approval for RAYOS, a drug used to treat a broad range of diseases including rheumatoid arthritis and polymyalgia rheumatic, among others. The company still has a long way to go before offering the drug, and is still very speculative. Running tight on liquidity, Horizon recently announced a move to raise more capital that will allow it to offer as many as 36.9 million new shares, compared to the near 34 million shares that are currently outstanding.

A couple key competitors for Horizon include Par Pharmaceutical Companies, Inc. (NYSE:PRX) and Perrigo Company (NASDAQ:PRGO). Both of these companies are a bit bigger than Horizon. Perrigo has beat EPS estimates the last four quarters and is expected to grow next quarter EPS by 18% from the same quarter last year. Perrigo has also decided to try its hand in the animal care market, purchasing Sergeant’s Pet Care Products for $285 million last week. This could be a key move for Perrigo to enter the $8 billion pet care industry, as it is already expected to add $0.12 to EPS next quarter.

Par missed last quarter estimates by 250%, but in July, the private equity firm TPG announced plans to purchase Par for $1.9 billion. The deal, valued at $50 per share, pushed Par’s stock up 50% year to date. Even with the share price spike, the company trades at a forward P/E of 14, much less than its trailing P/E of 22.

As far as Horizon, the company should be considered a speculative play, but has attracted some large interest from other notable pharma investors, with Farallon, Tang and Sutter now collectively owning over 20% of its outstanding shares. Also worth noting is the string of insider purchases between $3.49-$3.59 by a company director, where the company currently trades around $3.50. For a complete look at the insider and hedge fund sentiment surrounding Horizon Pharma, continue reading here.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!